O6-Methylguanine-DNA methyltransferase in glioma therapy: Promise and problems

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 1, 2012, Pages 71-82

  Silber, John R ^a   Bobola, Michael S ^a   Blank, A ^a,b   Chamberlain, Marc C ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

Alkylating agents; Biomarker; Chemotherapy resistance; Glioblastoma; Glioma; MGMT

Indexed keywords

6 O BENZYLGUANINE; 6 O CHLOROETHYLGUANINE; 6 O METHYLGUANINE; ALKYLATING AGENT; CARMUSTINE; GUANINE DERIVATIVE; LOMEGUATRIB; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BRAIN; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CPG ISLAND; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG RESPONSE; ENZYME ACTIVITY; GENE; GENE EXPRESSION REGULATION; GENE STRUCTURE; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MGMT GENE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; TUMOR CELL LINE;

BRAIN NEOPLASMS; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 84859789534     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.12.004     Document Type: Review

References (110)

1. Mitra S. MGMT: a personal perspective. DNA Repair 2007, 6:1064-1070.
2. 6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy. DNA Repair 2007, 6:1100-1115.
3. Samson L., Cairns J. A new pathway for DNA repair in Escherichia coli. Nature 1977, 267:281-283.
4. Weller M., Stupp R., Reifenberger G., Brandes A.A., van den Bent M.J., Wick W., Hegi M.E. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat. Rev. Neurol. 2010, 6:39-51.
5. von Deimling A., Korshunov A., Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 2011, 21:74-87.
6. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466.
7. van den Bent M.J., Dubbink H.J., Sanson M., van der Lee-Haarloo C.R., Hegi M., Jeuken J.W., Ibdaih A., Brandes A.A., Taphoorn M.J., Frenay M., Lacombe D., Gorlia T., Dinjens W.N., Kros J.M. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. 2009, 27:5881-5886.
8. Wick W., Hartmann C., Engel C., Stoffels M., Felsberg J., Stockhammer F., Sabel M.C., Koeppen S., Ketter R., Meyermann R., Rapp M., Meisner C., Kortmann R.D., Pietsch T., Wiestler O.D., Ernemann U., Bamberg M., Reifenberger G., von Deimling A., Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 2009, 27:5874-5880.
9. Kaina B., Christmann M., Naumann S., Roos W.P. MGMT: key node in the battle against genotoxicity, carcinogenicity, and apoptosis induced by alkylating agents. DNA Repair 2007, 6:1079-1099.
10. 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell. Mol. Life Sci. 2010, 67:3663-3681.
11. Mrugala M.M., Chamberlain M.C. Mechanisms of disease: temozolomide and glioblastoma look to the future. Nat. Clin. Pract. Oncol. 2008, 59:476-486.
12. Pegg A.E. Repair of O(6)-alkylguanine by alkyltransferases. Mutat. Res. 2000, 462:83-100.
13. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 2004, 4:296-307.
14. 6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis 2007, 28:1111-1116.
15. Kleihues P., Lantos L.P., Magee P.N. Chemical carcinogenesis in the nervous system. Int. Rev. Exp. Pathol. 1976, 15:153-232.
16. Schlegel J., Stumm G., Mennel H.D. Chemical carcinogenesis in the nervous system: past and future. Exp. Toxicol. Pathol. 1994, 45:455-466.
17. Wrensch M., Minn Y., Chew T., Bondy M., Berger M.S. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002, 4:278-299.
18. 6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:6941-6946.
19. 6-Methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin. Cancer Res. 1999, 5:807-814.
20. 6-methylguanine-DNA methyltransferase-mediated innate chloroethylnitrosourea resistance in human tumor cell lines. Mol. Pharmacol. 1997, 52:815-820.
21. 6-methylguanine-DNA methyltransferase gene. Cancer Res. 1997, 57:3672-3677.
22. Gardiner-Garden M., Frommer M. CpG islands in vertebrate genomes. J. Mol. Biol. 1987, 196:261-282.
23. 6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer. Res. 2009, 29:3741-3750.
24. 6-methylguanine. Mutagenesis 2002, 17:483-487.
25. Jacinto F.V., Esteller M. MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair 2007, 6:1155-1160.
26. Nagarajan R.P., Costello J.F. Epigenetic mechanisms in glioblastoma multiforme. Semin. Cancer Biol. 2009, 19:188-197.
27. 6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J. Biol. Chem. 1994, 269:17228-17237.
28. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol. Cell. Biol. 1997, 17:5612-5619.
29. 6-methylguanine-DNA methyltransferase promoter region as a marker of gene silencing. Mol. Carcinog. 1999, 24:85-89.
30. 6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 2003, 22:8835-8844.
31. Kitange G.J., Carlson B.L., Mladek A.C., Decker P.A., Schroeder M.A., Wu W., Grogan P.T., Giannini C., Ballman K.V., Buckner J.C., James C.D., Sarkaria J.N. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J. Neurooncol. 2009, 92:23-31.
32. Christmann M., Nagel G., Horn S., Krahn U., Wiewrodt D., Sommer C., Kaina B. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int. J. Cancer 2010, 127:2106-2118.
33. 6-methylguanine-DNA methyltransferase promoter reduces transcription. Biochim. Biophys. Acta 1994, 1217:141-146.
34. Costello J.F., Futscher B.W., Kroes R.A., Pieper R.O. Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines. Mol. Cell. Biol. 1994, 14:6515-6521.
35. 6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. Mol. Cancer Ther. 2005, 4:61-69.
36. 6-Methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res. 1998, 58:1068-1073.
37. Wiewrodt D., Nagel G., Dreimüller N., Hundsberger T., Perneczky A., Kaina B. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome. Int. J. Cancer 2008, 122:1391-1399.
38. 6-Methylguanine-DNA methyltransferase deficiency in developing brain: implications for brain tumorigenesis. DNA Repair 2007, 6:1127-1133.
39. 6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines. Mol. Carcinog. 1995, 13:81-88.
40. 6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin. Cancer Res. 1996, 2:735-741.
41. Bobola M.S., Kolstoe D.D., Blank A., Silber J.R. Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. Mol. Cancer Ther. 2010, 9:1208-1218.
42. 6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75:212-219.
43. Bodell W.J., Pongracz K. Chemical synthesis and detection of the cross-link 1-[N3-(2'-deoxycytidyl)]-2-[N1-(2'-deoxyguanosinyl)]ethane in DNA reacted with 1-(2-chloroethyl)-1-nitrosourea. Chem. Res. Toxicol. 1993, 6:434-438.
44. Newlands E.S., Stevens M.F., Wedge S.R., Wheelhouse R.T., Brock C. Temozolomide a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. 1997, 23:35-61.
45. Marchesi F., Turriziani M., Tortorelli G., Avisati G., Torino F., De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol. Res. 2007, 56:275-287.
46. 6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle 2010, 9:1168-1178.
47. Ludlum D.B. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat. Res. 1990, 233:117-126.
48. Ludlum D.B. The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. Cancer Invest. 1997, 15:588-598.
49. 6-methylguanine-DNA methyltransferase and chloroethylnitrosourea-treated DNA. Cancer Res. 1992, 52:6052-6058.
50. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
51. Gilbert M.R., Kuhn J., Lamborn K.R., Lieberman F., Wen P.Y., Mehta M., Cloughesy T., Lassman A.B., Deangelis L.M., Chang S., Prados M. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J. Neurooncol. 2011, [Epub ahead of print].
52. Belanich M., Pastor M., Randall T., Guerra D., Kibitel J., Alas L., Li B., Citron M., Wasserman P., White A., Eyre H., Jaeckle K., Schulman S., Rector D., Prados M., Coons S., Shapiro W., Yarosh D. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 1996, 56:783-788.
53. 6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J. Clin. Oncol. 1998, 16:3310-3315.
54. 6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J. Neurooncol. 2004, 70:333-340.
55. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin. Cancer Res. 2005, 11:5167-5174.
56. 6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J. Clin. Oncol. 2007, 25:1470-1475.
57. Capper D., Mittelbronn M., Meyermann R., Schittenhelm J. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol. 2008, 115:249-259.
58. Shah N., Lin B., Sibenaller Z., Ryken T., Lee H., Yoon J.G., Rostad S., Foltz G. Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One 2011, 6:e16146.
59. Cahill D.P., Levine K.K., Betensky R.A., Codd P.J., Romany C.A., Reavie L.B., Batchelor T.T., Futreal P.A., Stratton M.R., Curry W.T., Lafrate A.J., Louis D.N. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin. Cancer Res. 2007, 13:2038-2045.
60. Rodriguez F.J., Thibodeau S.N., Jenkins R.B., Schowalter K.V., Caron B.L., O'neill B.P., James C.D., Passe S., Slezak J., Giannini C. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl. Immunohistochem. Mol. Morphol. 2008, 16:59-65.
61. 6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008, 18:520-532.
62. 6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J. Neurooncol. 2010, 97:311-322.
63. 6-methylguanine-DNA methyltransferase. Oncol. Res. 1992, 5:83-86.
64. 6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am. J. Surg. Pathol. 2008, 32:1220-1227.
65. Sylvester R.K., Steen P., Tate J.M., Mehta M., Petrich R.J., Berg A., Kolesar J. Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients. Anticancer Drugs 2011, 22:104-110.
66. Crinière E., Kaloshi G., Laigle-Donadey F., Lejeune J., Auger N., Benouaich-Amiel A., Everhard S., Mokhtari K., Polivka M., Delattre J.Y., Hoang-Xuan K., Thillet J., Sanson M. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J. Neurooncol. 2007, 83:173-179.
67. Felsberg J., Rapp M., Loeser S., Fimmers R., Stummer W., Goeppert M., Steiger H.J., Friedensdorf B., Reifenberger G., Sabel M.C. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin. Cancer Res. 2009, 15:6683-6693.
68. Weller M., Felsberg J., Hartman C., Berger H., Steinbach J.P., Schramm J., Westphal M., Schackert G., Simon M., Tonn J.C., Heese O., Krex D., Nikkhah G., Pietsch T., Wiestler O., Reifenberger G., von Deimling A., Loeffler M. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J. Clin. Oncol. 2009, 27:5743-5750.
69. Brandes A.A., Franceschi E., Tosoni A., Benevento F., Scopece L., Mazzocchi V., Bacci A., Agati R., Calbucci F., Ermani M. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009, 115:3512-3518.
70. Stupp R., Hegi M.E., Neyns B., Goldbrunner R., Schlegel U., Clement P.M., Grabenbauer G.G., Ochsenbein A.F., Simon M., Dietrich P.Y., Pietsch T., Hicking C., Tonn J.C., Diserens A.C., Pica A., Hermisson M., Krueger S., Picard M., Weller M. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2010, 28:2712-2718.
71. Herrlinger U., Rieger J., Koch D., Loeser S., Blaschke B., Kortmann R.D., Steinbach J.P., Hundsberger T., Wick W., Meyermann R., Tan T.C., Sommer C., Bamberg M., Reifenberger G., Weller M. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J. Clin. Oncol. 2006, 24:4412-4417.
72. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B., Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343:1350-1354.
73. Krex D., Klink B., Hartmann C., von Deimling A., Pietsch T., Simon M., Sabel M., Steinbach J.P., Heese O., Reifenberger G., Weller M., Schackert G. Long-term survival with glioblastoma multiforme. Brain 2007, 130:2596-2606. German Glioma Network.
74. Martinez R., Schackert G., Yaya-Tur R., Rojas-Marcos I., Herman J.G., Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J. Neurooncol. 2007, 83:91-93.
75. Paz M.F., Yaya-Tur R., Rojas-Marcos I., Reynes G., Pollan M., Aguirre-Cruz L., García-Lopez J.L., Piquer J., Safont M.J., Balaña C., Sanchez-Cespedes M., García-Villanueva M., Arribas L., Esteller M. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res. 2004, 10:4933-4938.
76. Everhard S., Kaloshi G., Crinière E., Benouaich-Amiel A., Lejeune J., Marie Y., Sanson M., Kujas M., Mokhtari K., Hoang-Xuan K., Delattre J.Y., Thillet J. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann. Neurol. 2006, 60:740-743.
77. Kesari S., Schiff D., Drappatz J., LaFrankie D., Doherty L., Macklin E.A., Muzikansky A., Santagata S., Ligon K.L., Norden A.D., Ciampa A., Bradshaw J., Levy B., Radakovic G., Ramakrishna N., Black P.M., Wen P.Y. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin. Cancer Res. 2009, 15:330-337.
78. Herman J.G., Graff J.R., Myöhänen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:9821-9826.
79. Mikeska T., Bock C., El-Maarri O., Hübner A., Ehrentraut D., Schramm J., Felsberg J., Kahl P., Büttner R., Pietsch T., Waha A. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J. Mol. Diagn. 2007, 9:368-381.
80. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999, 59:793-797.
81. Shames D.S., Minna J.D., Gazdar A.F. Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett. 2007, 25:187-198.
82. 6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J. Mol. Diagn. 2008, 10:332-337.
83. Jeuken J.W., Cornelissen S.J., Vriezen M., Dekkers M.M., Errami A., Sijben A., Boots-Sprenger S.H., Wesseling P. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab. Invest. 2007, 87:1055-1065.
84. Cankovic M., Mikkelsen T., Rosenblum M.L., Zarbo R.J. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab. Invest. 2007, 87:392-397.
85. Douglas M.P., Rogers S.O. DNA damage caused by common cytological fixatives. Mutat. Res. 1998, 401:77-88.
86. Gavrilov A., Razin S.V. Formaldehyde fixation of cells does not greatly reduce the ability to amplify cellular DNA. Anal. Biochem. 2009, 390:94-96.
87. 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 2008, 26:4189-4199.
88. Sciuscio D., Diserens A.C., van Dommelen K., Martinet D., Jones G., Janzer R.C., Pollo C., Hamou M.F., Kaina B., Stupp R., Levivier M., Hegi M.E. Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin. Cancer Res. 2011, 17:255-266.
89. Westphal M., Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat. Neurosci. 2011, 12:495-508.
90. 6-methylguanine-DNA methyltransferase in Mex- human cells. Cancer Res. 1992, 52:5257-5263.
91. Stupp R., Hegi M.E. Methylguanine methyltransferase testing in glioblastoma: when and how?. J. Clin. Oncol. 2007, 25:1459-1460.
92. Flusberg B.A., Webster D.R., Lee J.H., Travers K.J., Olivares E.C., Clark T.A., Korlach J., Turner S.W. Direct detection of DNA methylation during single-molecule, real-time sequencing. Nat. Methods 2010, 7:461-465.
93. 6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol. Cancer Ther. 2006, 5:2531-2539.
94. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
95. Vogelbaum M.A., Berkey B., Peereboom D., Macdonald D., Giannini C., Suh J.H., Jenkins R., Herman J., Brown P., Blumenthal D.T., Biggs C., Schultz C., Mehta M. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro. Oncol. 2009, 11:167-175.
96. Rivera A.L., Pelloski C.E., Gilbert M.R., Colman H., De La Cruz C., Sulman E.P., Bekele B.N., Aldape K.D. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro. Oncol. 2010, 12:116-121.
97. Brandes A.A., Franceschi E., Tosoni A., Bartolini S., Bacci A., Agati R., Ghimenton C., Turazzi S., Talacchi A., Skrap M., Marucci G., Volpin L., Morandi L., Pizzolitto S., Gardiman M., Andreoli A., Calbucci F., Ermani M. O(6)-Methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro. Oncol. 2010, 12:283-288.
98. Bobola M.S., Varadarajan S., Smith N.W., Goff R.D., Kolstoe D.D., Blank A., Gold B., Silber J.R. Human glioma cell sensitivity to the sequence-specific alkylating agent methyl-lexitropsin. Clin. Cancer Res. 2007, 13:612-620.
99. Hegi M.E., Sciuscio D., Murat A., Levivier M., Stupp R. Epigenetic deregulation of DNA repair and its potential for therapy. Clin. Cancer Res. 2009, 15:5026-5031.
100. 6-methylguanine: implications for WRN function. DNA Repair 2004, 3:629-638.
101. Paulsen R.D., Cimprich K.A. The ATR pathway: fine-tuning the fork. DNA Repair 2007, 6:953-966.
102. Lange S.S., Takata K., Wood R.D. DNA polymerases and cancer. Nat. Rev. Cancer 2011, 11:96-110.
103. Huertas P. DNA resection in eukaryotes: deciding how to fix the break. Nat. Struct. Mol. Biol. 2010, 17:11-16.
104. Abbotts R., Madhusudan S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat. Rev. 2010, 36:425-435.
105. Bobola M.S., Emond M.J., Blank A., Meade E.H., Kolstoe D.D., Berger M.S., Rostomily R.C., Silbergeld D.L., Spence A.M., Silber J.R. Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy. Clin. Cancer Res. 2004, 10:7875-7883.
106. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., Verhaak R.G., Hoadley K.A., Hayes D.N., Perou C.M., Schmidt H.K., Ding L., Wilson R.K., Van Den Berg D., Shen H., Bengtsson H., Neuvial P., Cope L.M., Buckley J., Herman J.G., Baylin S.G., Laird P.W., Aldape K. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522. Cancer Genome Atlas Research Network.
107. Bredel M., Scholtens D.M., Yadav A.K., Alvarez A.A., Renfrow J.J., Chandler J.P., Yu I.L., Carro M.S., Dai F., Tagge M.J., Ferrarese R., Bredel C., Phillips H.S., Lukac P.J., Robe P.A., Weyerbrock A., Vogel H., Dubner S., Mobley B., He X., Scheck A.C., Sikic B.I., Aldape K.D., Chakravarti A., Harsh G.R. NFKBIA deletion in glioblastomas. N. Engl. J. Med. 2011, 364:627-637.
108. Lee Y., Scheck A.C., Cloughesy T.F., Lai A., Dong J., Farooqi H.K., Liau L.M., Horvath S., Mischel P.S., Nelson S.F. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med. Genomics 2008, 1:52.
109. Etcheverry A., Aubry M., de Tayrac M., Vauleon E., Boniface R., Guenot F., Saikali S., Hamlat A., Riffaud L., Menei P., Quillien V., Mosser J. DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics 2010, 11:701.
110. Lai A., Kharbanda S., Pope W.B., Tran A., Solis O.E., Peale F., Forrest W.F., Pujara K., Carrillo J.A., Pandita A., Ellingson B.M., Bowers C.W., Soriano R.H., Schmidt N.O., Mohan S., Yong W.H., Seshagiri S., Modrusan Z., Jiang Z., Aldape K.D., Mischel P.S., Liau L.M., Escovedo C.J., Chen W., Nghiemphu P.L., James C.D., Prados M.D., Westphal M., Lamszus K., Cloughesy T., Phillips H.S. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J. Clin. Oncol. 2011, 29:4482-4490.